KRAS and colorectal carcinoma: We next evaluated PEAK2 cancer activity by transducing a rat PEAK2 expression construct (named PEAK2Myc) in KRAS-mutated HCT116 CRC cells that expressed low endogenous PEAK2 (Figure 4A).